Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

October 30, 2027

Conditions
EpilepsyStatus Epilepticus
Interventions
DRUG

Lacosamide (LCM)

Intravenous lacosamide is given for the treatment of seizure termination in patients with status epilepticus

Trial Locations (1)

510260

The Second Affiliated Hospital of Guangzhou Medical Universty, Guangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital of Jinan University

OTHER

collaborator

Guangzhou First People's Hospital

OTHER

collaborator

Southern Medical University, China

OTHER

collaborator

Guangdong 999 Brain Hospital

OTHER

lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER